Skip to main content

Peer Review reports

From: Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

Original Submission
4 Oct 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
5 Dec 2021 Reviewed Reviewer Report
8 Dec 2021 Reviewed Reviewer Report - Ersin Hatice Karslıoğlu
12 Jan 2022 Author responded Author comments - Pierre Chevalier
Resubmission - Version 4
12 Jan 2022 Submitted Manuscript version 4
14 Feb 2022 Author responded Author comments - Pierre Chevalier
Resubmission - Version 5
14 Feb 2022 Submitted Manuscript version 5
24 Feb 2022 Author responded Author comments - Pierre Chevalier
Resubmission - Version 6
24 Feb 2022 Submitted Manuscript version 6
24 Feb 2022 Author responded Author comments - Pierre Chevalier
Resubmission - Version 7
24 Feb 2022 Submitted Manuscript version 7
Publishing
28 Feb 2022 Editorially accepted
7 Jun 2022 Article published 10.1186/s12888-022-03914-2

You can find further information about peer review here.

Back to article page